cas 613-45-6|| where to buy 2,4-Dimethoxybenzaldehyde

Название продукции:2,4-Dimethoxybenzaldehyde

IUPAC Name:2,4-dimethoxybenzaldehyde

Упаковочная единица	Доступно для заказа	Цена ($)	Количество
CM243667-500g	in stock	ưưȁ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 613-45-6 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:613-45-6; Молекулярная формула:C9H10O3; Точка плавления:-; Smiles-код:O=CC1=CC=C(OC)C=C1OC; Плотность:

: Номер в каталоге:CM243667; Молекулярная масса:166.18; Точка кипения:307.8°C at 760 mmHg; Номер Mdl:MFCD00003311; Хранение:Keep in Inert atmosphere, store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Fezolinetant; Dec 10, 2023, VEOZA (fezolinetant) approved by European Commission for treatment of vasomotor symptoms associated with menopause.
VEOZAH is the first and only neurokinin 3 (NK3) receptor antagonist that blocks NKB from binding on KNDy neurons to help reduce heat signals that trigger VMS. First-in-class fezolinetant brings women a new nonhormonal therapy for hot flashes.
In May 2023, FDA has approved VEOZA(fezolinetant) 45 mg once daily for the treatment of moderate to severe VMS due to menopause.

: JNT-517; Jnana Therapeutics announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor of the phenylalanine (Phe) transporter SLC6A19, is being evaluated as a potential first-in-class oral treatment for PKU across all ages and genotypes. Based on these positive mid-term results, Jnana has adjusted its phase 1b clinical trial design to support the critical phase 3 clinical trial of JNT-517 starting in the first half of 2025.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.